BRAF inhibitors such as PLX4032 have shown promising initial results in melanoma, but have suffered from drug resistance after 6-9 months. This has led to combination trials with AKT and MEK inhibitors to see if the time before drug resistance sets in can be extended.
However, recent research published in Cancer Research suggests that loss of PTEN function may be another mechanism of resistance. Researchers have looked at what may happen with the next generation of BRAF inhibitors, PLX4720.
Sally Church in a thoughtful post on Pharma Strategy Blog discusses how the insights from this latest research may impact oncology drug development strategy.